摘要
人表皮生长因子受体(Her)2是一种具有酪氨酸激酶活性的跨膜糖蛋白,其表达与肿瘤的形成、恶性程度及预后密切相关。Her2高表达是胃癌预后不良的标记物之一,针对Her2的分子靶向药物曲妥珠单抗和拉帕替尼与化疗药物联合治疗胃癌的初步临床研究均获得显著效果。本文综述Her2在胃癌中的表达及临床意义。
Human epidermal growth factor receptor (Her)2 is a kind of trans-membrane glycoprotein with tyrosine kinase activity. Its expression is closely related with tumor formation, malignancy grade and prognosis. Her2 overexpression is a marker of poor prognosis in gastric cancer. As molecular targeted drugs against Her2, trastuzumab and lapatinib have shown good clinical results when they combine with chemotherapy to treat gastric cancer. This review focuses on the expression and clinical significance.
出处
《世界临床药物》
CAS
2011年第8期499-502,共4页
World Clinical Drug
基金
上海交通大学医学院科技基金项目(项目编号:09XJ22002)